

Elgemtumab

Cat. No.:	HY-P99936
CAS No.:	1512559-37-3
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential ^[1] .
In Vivo	<p>Elgemtumab(LJM716)(i.v., 20 mg/kg,once) can reduce pHER3 by 52% and pAKT by 84% in SCID mice with BT474 breast cancer xenografts; while in BxPC-3 pancreatic xenografts In SCID mice, it resulted in a maximum inhibition of pHER3 of 86% and a maximum inhibition of pAKT of 74%^[1].</p> <p>Elgemtumab (LJM716) (20 mg/kg, every other day, 35 days) slows tumor growth in NSG mice with BT474 breast cancer xenografts^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

[1]. Andrew P Garner, et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA